Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 184
- Registration Number
- NCT00531284
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 312
- Registration Number
- NCT00511238
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Northwest Cancer Center, Houston, Texas, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT00150462
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.